Implant reduces intraocular pressure

29 December 2023

The US Food and Drug Administration (FDA) has approved an intraocular implant for the treatment of open-angle glaucoma or ocular hypertension. The capsule placed in the angle of the chamber continuously releases the prostaglandin analog travoprost, which improves the outflow of aqueous humor.
The implantation of “iDose” frees patients from the daily use of eye drops. It is implanted in the iridocorneal angle between the cornea and the iris. There it penetrates the sclera with its tip, where it is firmly anchored with a barb. The most common ocular side effects, which occurred in 2 % to 6 % of iDose TR patients, were increases in intraocular pressure, iritis, dry eyes and visual field defects, which were mostly mild and improved on their own.
Author(s)	Source
FDA, Reference ID: 5292678	NDA 218010 Page 4 – accessdata.fda.gov
This is a post of a scientific or business information. The information given here is checked thoroughly by “Implant-Register”. However we can´t be responsible for the content. The content usually is shortened to make it understandable for many. Read the linked original text if you are interested. Contact the publisher, if you have questions. You may inform us about changes of the information to improve the Register.
Comments: n/a let us know